ライフサイエンスコーパス: head and neck carcinoma

1 tumors and increased EGFR phosphorylation in head and neck carcinoma.

2 -015 injection in 37 patients with recurrent head and neck carcinoma.

3 d H19 loci play a role in the oncogenesis of head and neck carcinoma.

4 is a driving force in cervical, bladder and head-and-neck carcinoma.

5 interface resembling the expression on human head and neck carcinomas.

6 can be exploited for the treatment of human head and neck carcinomas.

7 y develop in patients previously treated for head and neck carcinomas.

8 n of C225 and radiotherapy for patients with head and neck carcinomas.

9 tract tumors in patients with prior lung or head and neck carcinomas.

10 oved for use in patients with colorectal and head and neck carcinomas.

11 significant antitumor activity against human head and neck carcinoma A253 cells in vitro.

12 ethality in vitro in the p53-defective human head and neck carcinoma A253 cells.

13 at ablating these neurons in mouse models of head and neck carcinoma and melanoma reduced the infiltr

14 It has been reported in about 45% of head and neck carcinomas and in other cancers including

15 types of altered fractionation schedules in head and neck carcinomas are examined in this review.

16 ariety of cancer cell lines, including SQ20B head and neck carcinoma cells and U251 glioblastoma cell

17 -FHIT-transduced human lung cancer cells and head and neck carcinoma cells with FHIT gene abnormaliti

18 propose to study the effect of IGF1 on human head and neck carcinoma cells.

19 elial cells, as well as other EBV-associated head-and-neck carcinomas, exhibit oncogenic phenotypes c

20 avirus (HPV) DNAs isolated from cervical and head and neck carcinomas frequently contain nucleotide s

21 rvival (OS) of patients with stage III or IV head and neck carcinoma (HNC).

22 ncers also are found in approximately 25% of head and neck carcinomas (HNCs), especially those arisin

23 r future clinical trials of BNP1350 in human head and neck carcinoma, in vitro studies were carried o

24 dard fractionation (SFX) in locally advanced head and neck carcinoma (LA-HNC).

25 determined in nude mice with a subcutaneous head and neck carcinoma model (FaDu).

26 tion or irradiation during treatment in both head and neck carcinoma models investigated, whereas (18

27 le; mean age, 61.77 years + or - 10.12) with head and neck carcinomas not involving the tonsils were

28 Significantly elevated risk of head and neck carcinoma occurred in survivors of soft ti

29 es resulting from trauma, mycotic infection, head and neck carcinomas or complications related to the

30 M213A expression was correlated inversely in head and neck carcinoma samples according to The Cancer

31 Consistently, in human lung and head and neck carcinomas, STAT3 acetylation and phosphor

32 We previously showed that in HEp3 human head and neck carcinoma, the extracellular signal-regula

33 n-small cell lung carcinomas, lymphomas, and head and neck carcinomas, this alteration was found in 2

34 us cell carcinoma (HNSCC) and 10 nonsquamous head and neck carcinoma tumor tissues, as compared with

35 arcinomas (147 breast, 116 prostate, and 122 head and neck carcinomas) were subjected to whole genome